Home Newsfeeds Cogent Comms Hldgs Q2 EPS $0.41 Beats $0.25 Estimate

Cogent Comms Hldgs Q2 EPS $0.41 Beats $0.25 Estimate

Cogent Comms Hldgs (NASDAQ:CCOI) reported quarterly earnings of $0.41 per share which beat the analyst consensus estimate of $0.25 by 64 percent. This is a 105 percent increase over earnings of $0.20 per share from the

byBenzinga Newsdesk

August 4, 2022

1 minute read

Earnings

Recap: Stitch Fix Q1 Earnings

By Benzinga Insights

December 5, 5:20 PM

Stitch Fix (NASDAQ:SFIX) reported its Q1 earnings results on Tuesday, December 5, 2023 at 04:05 PM. Here’s what…

SFIX

Royal Gold’s Growth Remains ‘Modest,’ Says Bullish Analyst: ‘This Could Change’

By Priya Nigam

March 27, 11:53 AM

Royal Gold Inc (NASDAQ: RGLD) announced its second-quarter dividend.

RGLD

Fidelity National Finl Q2 EPS $1.90 Beats $1.61 Estimate, Sales $2.63B Miss $3.41B Estimate

By Benzinga Newsdesk

August 2, 5:54 PM

Fidelity National Finl (NYSE:FNF) reported quarterly earnings of $1.90 per share which beat the analyst consensus estimate of $1.61 by 18.01 percent. This is a 7.77 percent decrease over earnings of $2.06 per share from

FNF

U.S. FDA Approves Subcutaneous Administration Of Takeda’s ENTYVIO For Maintenance Therapy In Moderately To Severely Active Ulcerative Colitis

By Happy Mohamed

September 27, 4:27 PM

− ENTYVIO Is the Only FDA-Approved Ulcerative Colitis Biologic That Offers the Choice of Intravenous or Subcutaneous Maintenance Therapy Takeda ((TAK) today announced that the U.S. Food and Drug

TAK

Cogent Comms Hldgs Q2 EPS $0.41 Beats $0.25 Estimate

Related Posts

Recap: Stitch Fix Q1 Earnings

Royal Gold’s Growth Remains ‘Modest,’ Says Bullish Analyst: ‘This Could Change’

Fidelity National Finl Q2 EPS $1.90 Beats $1.61 Estimate, Sales $2.63B Miss $3.41B Estimate

U.S. FDA Approves Subcutaneous Administration Of Takeda’s ENTYVIO For Maintenance Therapy In Moderately To Severely Active Ulcerative Colitis